People with opioid use disorder in British Columbia who received methadone had a 37- to 40-percent lower rate of treatment discontinuation compared with those who received buprenorphine/naloxone. The new research evaluated the risk of treatment discontinuation and mortality in people prescribed opioid agonist treatment (OAT) over a 10-year period.